Collectively, these findings suggest that class I PI3K and/or mTOR signaling suppresses Wnt/β-catenin signaling in ER− breast cancer cell lines, although whether Wnt activation occurs in primary human ER− breast tumors treated with PI3K inhibitors remains to be determined. This evidence concerns the gene MTOR and breast cancer.